| ANIMAL | evidence | Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. | Retatrutide | Glycemic control · animal | 2025-01-01 |
| ANIMAL | evidence | LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. | LY3437943 | Weight & fat loss · animal | 2022-09-06 |
| PRECLINICAL | evidence | Beyond weight loss: multisystem benefits of obesity medications. | Retatrutide | Weight & fat loss | 2026-08-01 |
| PRECLINICAL | evidence | Retatrutide and the urinary tract infection signal: Is the answer hidden in timing? | Retatrutide | — | 2026-07-23 |
| PRECLINICAL | evidence | Medical Treatments for Obesity: What Does the Future Have in Store? | Retatrutide | — | 2026-07-14 |
| PRECLINICAL | evidence | Retatrutide fact check: Has a man died after taking the unapproved weight loss jab? | Retatrutide | — | 2026-07-09 |
| PRECLINICAL | evidence | Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. | Retatrutide | Weight & fat loss | 2026-07-08 |
| PRECLINICAL | evidence | Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. | Retatrutide | — | 2026-07-01 |
| PRECLINICAL | evidence | Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. | Retatrutide | — | 2026-06-29 |
| PRECLINICAL | evidence | Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. | Retatrutide | — | 2026-06-16 |
| PRECLINICAL | evidence | A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. | Retatrutide | Gut barrier & GI healing | 2026-06-12 |
| PRECLINICAL | evidence | Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports. | Retatrutide | — | 2026-06-09 |
| PRECLINICAL | evidence | Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure. | Retatrutide | Weight & fat loss | 2026-06-06 |
| PRECLINICAL | evidence | Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050. | Retatrutide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. | Retatrutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. | Retatrutide | — | 2026-06-01 |
| PRECLINICAL | evidence | Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. | Retatrutide | Glycemic control | 2026-05-29 |
| PRECLINICAL | evidence | Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. | Retatrutide | Glycemic control | 2026-05-22 |
| PRECLINICAL | evidence | Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists. | Retatrutide | — | 2026-05-19 |
| PRECLINICAL | evidence | Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. | Retatrutide | Glycemic control | 2026-05-18 |
| PRECLINICAL | evidence | Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. | Retatrutide | Lipid & cardiovascular markers · n = 90977 | 2026-05-15 |
| PRECLINICAL | evidence | Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. | Retatrutide | — | 2026-05-14 |
| PRECLINICAL | evidence | Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. | Retatrutide | — | 2026-05-11 |
| PRECLINICAL | evidence | A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital. | Retatrutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. | Retatrutide | — | 2026-04-10 |
| PRECLINICAL | evidence | Retatrutide in type 2 diabetes mellitus and obesity: an overview. | LY3437943 | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. | Retatrutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. | Retatrutide | Liver health | 2026-04-01 |
| PRECLINICAL | evidence | Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. | Retatrutide | — | 2026-04-01 |
| PRECLINICAL | evidence | New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. | Retatrutide | Weight & fat loss | 2026-03-18 |
| PRECLINICAL | evidence | Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. | Retatrutide | Glycemic control | 2026-03-14 |
| PRECLINICAL | evidence | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. | Retatrutide | Glycemic control | 2026-03-11 |
| PRECLINICAL | evidence | Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. | Retatrutide | Glycemic control | 2026-03-05 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. | Retatrutide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | The role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review. | LY3437943 | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. | Retatrutide | — | 2026-02-19 |
| PRECLINICAL | evidence | Development of the Weight and Emotions Scale (WES). | Retatrutide | — | 2026-02-01 |
| PRECLINICAL | evidence | Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. | Retatrutide | — | 2026-01-26 |
| PRECLINICAL | evidence | [Nephrology : what's new in 2025]. | Retatrutide | Glycemic control | 2026-01-14 |
| PRECLINICAL | evidence | GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. | Retatrutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. | Retatrutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. | Retatrutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Metabolic inflammation at the adipose-brain axis. | Retatrutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. | Retatrutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. | Retatrutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Inotropic effects of retatrutide in isolated human atrial preparations. | LY3437943 | — | 2026-01-01 |
| PRECLINICAL | evidence | The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. | LY3437943 | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. | Retatrutide | — | 2025-12-01 |
| PRECLINICAL | evidence | Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. | Retatrutide | — | 2025-12-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. | Retatrutide | — | 2025-12-01 |